title: Motolimod effectively drives immune activation in advanced cancer patients.
abstract: A novel approach to immunotherapy is the activation of toll-like receptor 8 (TLR8). Motolimod, a selective TLR8 agonist can act in concert with approved immunotherapies to sensitize T cells and augment natural killer (NK) cell function. Despite treatment with chemotherapeutic agents and advance disease, cancer patients remain sensitive to motolimod.
authors.affiliation: VentiRx Pharmaceuticals Inc. , Seattle, WA, USA.
authors.forename: Gregory N
authors.initials: GN
authors.lastname: Dietsch